Understand the source comparison
Tirzepatide VIP Doses: Clinical Comparison
2.5mg weekly ~5–7% 1.4–1.7% 15–20% 4 weeks (starting dose) Initiates receptor activation; minimal side effects but subtherapeutic for most patients as maintenance dose 5mg weekly ~15% 1.9–2.1% 25–30% 4 weeks or maintenance First therapeutic threshold for many
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 2.5mg weekly
- ~5–7%
- 1.4–1.7%
- 15–20%
- 4 weeks (starting dose)
- Initiates receptor activation; minimal side effects but subtherapeutic for most patients as maintenance dose
- 5mg weekly
- ~15%
- 1.9–2.1%
- 25–30%
- 4 weeks or maintenance
- First therapeutic threshold for many patients; balance of efficacy and tolerability
- 7.5mg weekly
- ~17–18%
- 2.2–2.4%
- 30–35%
- Incremental benefit over 5mg; optimal dose for patients who plateau at lower levels
- 10mg weekly
- ~19–20%
- 2.3–2.5%
- 35–40%
- Near-maximal efficacy; GI side effects become dose-limiting for some patients
- 15mg weekly
- ~20.9%
- 2.4–2.6%
- 40–50%
- Maintenance
- Maximum validated dose; highest efficacy but also highest discontinuation rate due to adverse events